Stayble Therapeutics terminates agreement regarding liquidity provider

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB ("Lago"). The agreement will cease to be effective on September 29, 2023.

The purpose of the liquidity provider has been to increase the liquidity of stock trading and reduce the volatility of the Company's stock to facilitate trading. Stayble assesses that the liquidity of the stock is strong and that the need for a liquidity provider is no longer applicable. The agreement with Lago has now been terminated and will expire on September 29, 2023.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase 2b clinical trial in DDD and a Phase 1b trial in LDH.

Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser.